The FDA has accepted for Priority Review the BLA for tividenofusp alfa for the treatment of Hunter syndrome, also known as MPS II.

The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been ...